Actuate Therapeutics’ Quiet Period To Expire on September 23rd (NASDAQ:ACTU)

Actuate Therapeutics’ (NASDAQ:ACTU) quiet period is set to expire on Monday, September 23rd. Actuate Therapeutics had issued 2,800,000 shares in its IPO on August 13th. The total size of the offering was $22,400,000 based on an initial share price of $8.00. During the company’s quiet period, underwriters and any insiders involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Actuate Therapeutics Stock Performance

Shares of Actuate Therapeutics stock opened at $8.02 on Wednesday. The stock has a market cap of $153.26 million and a PE ratio of 53.47. Actuate Therapeutics has a 12 month low of $7.33 and a 12 month high of $10.16.

Insider Activity

In related news, Director Equity Cof Lp Bios purchased 500,000 shares of Actuate Therapeutics stock in a transaction that occurred on Wednesday, August 14th. The shares were acquired at an average cost of $8.00 per share, for a total transaction of $4,000,000.00. Following the transaction, the director now directly owns 1,259,427 shares in the company, valued at $10,075,416. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, major shareholder Leslie W. Kreis sold 24,999 shares of the firm’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $9.00, for a total transaction of $224,991.00. Following the transaction, the insider now directly owns 131,248 shares in the company, valued at approximately $1,181,232. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Equity Cof Lp Bios acquired 500,000 shares of the company’s stock in a transaction on Wednesday, August 14th. The stock was acquired at an average price of $8.00 per share, with a total value of $4,000,000.00. Following the acquisition, the director now owns 1,259,427 shares in the company, valued at approximately $10,075,416. The disclosure for this purchase can be found here. Corporate insiders own 19.90% of the company’s stock.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.